ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0470

Long-term Efficacy of Tocilizumab Monotherapy After Ultra-short Glucocorticoid Administration to Treat Giant Cell Arteritis – One Year Follow-up of the GUSTO Trial

Lisa Christ1, Luca Seitz2, Godehard Scholz1, Lukas Buetikofer3, Florian Kollert1, Stephan Reichenbach4 and Peter Villiger5, 1Department of Rheumatology and Immunology, University of Bern, Inselspital, Bern, Switzerland, 2Department of Rheumatology and Immunology, University of Bern, Inselspital, Switzerland, 3CTU Bern, University of Bern, Bern, Switzerland, 4University of Bern, Institute for Social and Preventive Medicine, Bern, Switzerland, 5Medical Center Monbijou, Rheumatology and Immunology, Bern, Switzerland

Meeting: ACR Convergence 2022

Keywords: clinical trial, giant cell arteritis, Vasculitis

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 12, 2022

Title: Vasculitis – Non-ANCA-Associated and Related Disorders Poster I: Giant Cell Arteritis

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: Two randomised controlled trials (RCT) [1, 2] demonstrated a glucocorticoid (GC)-sparing effect of tocilizumab (TCZ) of at least 50% in the treatment of giant cell arteritis (GCA). The GUSTO (Giant cell arteritis treatment with Ultra-Short glucocorticoids and TOcilizumab) trial was set up to evaluate the efficacy and safety of TCZ-monotherapy after a 3-day GC-pulse in new-onset GCA.

The objectives of this analysis were to explore the maintenance of remission 1 year after discontinuation of TCZ treatment. Data up to week 104 are presented.

Methods: Eighteen patients with newly diagnosed GCA were enrolled in this investigator-initiated, single-arm, single-center, open-label clinical trial [3]. Patients received 500 mg methylprednisolone intravenously for 3 consecutive days. Thereafter, GC treatment was discontinued and TCZ (8 mg/kg bodyweight) was administered intravenously, followed by weekly subcutaneous TCZ injections (162 mg) from day 10 until week 52. Patients in clinical remission stopped TCZ at week 52 and entered the follow-up study. Maintenance of efficacy at week 104 included the proportion of patients with complete relapse-free remission of disease at week 104, and time to first relapse after week 52.

Results: At baseline there were 12/18 female patients, and the median age was 72 (range 67-75) years. Overall, 15/18 complained cranial symptoms (10/18 jaw claudication, 6/18 visual symptoms), 10/18 suffered from polymyalgia rheumatica symptoms, 16/18 had positive cranial ultrasound, and 13/18 had characteristic histopathology. At week 52, 13/18 patients were in relapse-free remission and entered the follow-up study. 1/13 patients presented with a minor relapse at week 72. Remission was achieved after restart of TCZ-monotherapy. At week 104, 12/18 patients were in relapse-free remission.

Conclusion: After a 3-days pulse of methylprednisolone followed by 52 weeks of TCZ monotherapy, drug-free remission was maintained until week 104 in all but one patient entering long-term extension (12/13, 92%). This relapse rate is substantially lower than reported in the RCTs [1,2]. It may – at least in part – be explained by the patient characteristics (exclusively new diagnoses), and potentially by the initial 3-day GC pulse. As a proof-of-concept study, the protocol is not intended to be used in everyday clinical practice.

References
1. Villiger, et al. Lancet, 2016
2. Stone, et al. NEJM, 2017
3. Christ, et al. Lancet Rheumatol, 2021

Supporting image 1

Disease status of patients at each visit (Day 0 – week 104, n=18)


Disclosures: L. Christ, Novartis, Gilead, Roche, Pfizer, Bristol-Myers Squibb(BMS); L. Seitz, None; G. Scholz, None; L. Buetikofer, None; F. Kollert, Roche; S. Reichenbach, None; P. Villiger, Roche, Merck/MSD, AbbVie/Abbott, Pfizer, Novartis, Amgen, Bristol-Myers Squibb(BMS).

To cite this abstract in AMA style:

Christ L, Seitz L, Scholz G, Buetikofer L, Kollert F, Reichenbach S, Villiger P. Long-term Efficacy of Tocilizumab Monotherapy After Ultra-short Glucocorticoid Administration to Treat Giant Cell Arteritis – One Year Follow-up of the GUSTO Trial [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/long-term-efficacy-of-tocilizumab-monotherapy-after-ultra-short-glucocorticoid-administration-to-treat-giant-cell-arteritis-one-year-follow-up-of-the-gusto-trial/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/long-term-efficacy-of-tocilizumab-monotherapy-after-ultra-short-glucocorticoid-administration-to-treat-giant-cell-arteritis-one-year-follow-up-of-the-gusto-trial/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology